Compare Stocks

Morgan Stanley analyst Sean Laaman lowered the firm’s price target on Axsome Therapeutics (AXSM) to $223 from $249 and keeps an Equal Weight rating on the shares. The firm adjusted

Axsome Therapeutics, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Ram Selvaraju from H.C. Wainwright reiterated a Buy rating on the stock and has a

Axsome Therapeutics Inc. ($AXSM) announced an update on their ongoing clinical study. Study Overview: Axsome Therapeutics, Inc. is studying solriamfetol in adolescents with attention deficit hyperactivity disorder. The official title

Axsome Therapeutics Inc. ($AXSM) announced an update on their ongoing clinical study. Study Overview: Axsome Therapeutics Inc. (NASDAQ: AXSM) is evaluating solriamfetol in the Phase 3 study titled “A Phase

Axsome Therapeutics Inc. ($AXSM) announced an update on their ongoing clinical study. Study Overview: Axsome Therapeutics is evaluating the long-term safety of solriamfetol in children and adolescents with attention deficit

Mizuho lowered the firm’s price target on Axsome Therapeutics (AXSM) to $272 from $284 and keeps an Outperform rating on the shares. Published first on TheFly – the ultimate source

Deutsche Bank lowered the firm’s price target on Axsome Therapeutics (AXSM) to $245 from $267 and keeps a Buy rating on the shares following the Q3 report. Published first on

Morgan Stanley raised the firm’s price target on Axsome Therapeutics (AXSM) to $249 from $247 and keeps an Equal Weight rating on the shares. Published first on TheFly – the

Guggenheim analyst Yatin Suneja lowered the firm’s price target on Axsome Therapeutics (AXSM) to $250 from $275 and keeps a Buy rating on the shares as the firm adjusted estimates

BofA lowered the firm’s price target on Axsome Therapeutics (AXSM) to $264 from $276 and keeps a Buy rating on the shares. Q3 was largely in-line, but shares continue to